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Aspirin ingestion can induce a wide range of clinically recog-
nized allergic reactions, including acetyl salicylic acid (ASA)-
exacerbated respiratory disease (AERD), ASA-intolerant urti-
caria (AIU), chronic rhinitis, and anaphylaxis. Patients with AIU 
have high rates of atopy and increased total IgE levels,
1 but the 
pathogenic mechanism of AIU remains unclear. ASA is metab-
olized by UDP-glucuronosyltransferase 1A6 (UGT1A6), cyto-
chrome P4502C9 (CYP2C9), and N-acetyl transferase 2 (NAT2). 
Inter-individual differences in the activities of these enzymes 
may be the underlying cause of adverse ASA-related symptoms 
such as urticaria.
The two polymorphic enzymes CYP2C9 and UGT1A6 are in-
volved in hydroxylation and glucuronidation of ASA, respec-
tively.
2,3 Two known variant alleles of UGT1A6 result in amino 
acid changes at positions 181 and 184, and a 30–50% reduction 
in enzyme activity compared with wild type activity.
4 Similarly, 
two variant CYP2C9 alleles, CYP2C9*2 (R144C) and CYP2C9*3 
(I359L), produce slow metabolizing enzymes, with 5–30% of 
wild-type enzyme activity.
5 Variations in the enzymes that me-
tabolize ASA may play a role in ASA-related diseases such as ur-
ticaria.
Leukotriene overproduction is a possible risk factor for ASA 
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hypersensitivity, including AIU.
6 Cysteinyl leukotrienes are in-
activated by acetyl coenzyme A-dependent N-acetyltransferase 
(NAT). Thus, functional alterations in the NAT2 gene may con-
tribute to the risk for ASA-intolerant symptoms such as asth-
ma.
7 Genetically-determined rapid and slow acetylators pro-
duce variation in the elimination rates of xenobiotics, as well as 
in the levels of NAT2 in the liver and other tissues. Single nucle-
otide polymorphisms (SNPs) of the NAT2 gene are markers of 
atopic asthma, high serum IgE levels, and high blood eosino-
phil counts.
8
Based on the involvement of these enzymes in the metabo-
lism of ASA, we investigated the relationship between polymor-
phisms in UGT1A6, CYP2C9, and NAT2, and the occurrence of 
ASA-intolerant urticaria in a Korean population. In total, 148 
AIU patients (AIU group) and 260 normal healthy control sub-
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Acetyl salicylic acid (ASA) is metabolized by UDP-glucuronosyltransferase 1A6 (UGT1A6), cytochrome P4502C9 (CYP2C9), and N-acetyl transferase 
2 (NAT2). Variations in the activities of these enzymes may modulate adverse ASA-related symptoms such as urticaria. We examined whether poly-
morphisms in the UGT1A6, CYP2C9, and NAT2 genes are related to ASA-intolerant urticaria (AIU). The genotypes of 148 subjects with AIU (AIU 
group) and 260 normal healthy control subjects (NC group) were analyzed with respect to the following single nucleotide polymorphisms: CYP2C9 
−1188T>C and CYP2C9*3A1075C; UGT1A6 T181A A>G and UGT1A6 R184S A>C; and NAT2 9796A>T, NAT2 197G>A, NAT2 286G>A, NAT2 
9601A>G, and NAT2 9306A>G. There were significant differences in the allele frequencies for the CYP2C9 polymorphisms between the two groups. 
The frequency of the minor allele CYP2C9 −1188T>C was significantly higher in the AIU group than in the NC group (P=0.005). The frequency of the 
variant genotype CC was higher in the AIU group compared with the controls in both the co-dominant (P=0.007) and recessive models (P=0.012). 
The frequency of haplotype 2 [CA] was also significantly higher in the AIU group in both the co-dominant (P=0.006) and dominant models (P=0.012). 
There was no significant difference in genotype frequencies for any of the UGT1A6 or NAT2 polymorphisms between the two groups. Clinical pa-
rameters did not differ according to genotype. These results suggest that the C allele of CYP2C9 −1188T>C may be associated with AIU.
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jects (NC) were enrolled at the Ajou University Hospital in Su-
won, Korea. AIU was defined by a positive result on an ASA oral 
provocation test, which was performed using 500 mg of ASA 
(Rhonal; KunWha Pharmaceutical Co., Seoul, Korea).
5 A con-
trol group (NC) with no personal or family history of allergic 
diseases or past history of ASA hypersensitivity was recruited 
from the general population. Informed consent was obtained 
from all subjects prior to enrollment, and the study was approved 
by the Ajou University Hospital Institutional Review Board. Skin 
prick testing was performed with 55 common aero-allergens 
(Bencard Co., West Sussex, UK). Atopy was defined as one or 
more positive reactions to common inhalant allergens. Total 
IgE concentration was measured using a UniCAP system (Phar-
macia Diagnostics, Uppsala, Sweden), according to the manu-
facturer’s instructions. SNPs in the promoter and/or exons of 
the CYP2C9, UGT1A6, and NAT2 genes of 40 healthy volunteers 
were sequenced using an ABI Prism 3100 DNA analyzer (Ap-
plied Biosystems, Foster City, CA, USA). We identified two SNPs 
in CYP2C9, one in the promoter (CYP2C9 −1188T>C) and one 
in an exon (CYP2C9*3A1075C). For UGT1A6, we selected two 
exonic SNPs (UGT1A6 T181A A>G and UGT1A6 R184S A>C). 
We confirmed five SNPs for NAT2 (NAT2 9796A>T, NAT2 
197G>A, NAT2 286G>A, NAT2 9601A>G, and NAT2 9306A>G). 
These SNPs were genotyped using primer extension and a 
SNAPshot ddNTP primer extension kit (Applied Biosystems).
Differences in mean values of phenotypic characteristics 
among the patients were compared using a Student’s t-test for 
continuous variables or the χ2 test for categorical variables. Dif-
ferences in genotype frequency between the two groups were 
examined using the χ2 test. A logistic regression recessive analy-
sis model was used after adjustment for age and gender covari-
ates, followed by a multiple comparison test. All statistical anal-
yses were performed using SPSS version 12.0 (SPSS Inc., Chica-
go, IL, USA). In all analyses, P<0.05 was considered statistically 
significant.
The mean age was significantly higher in the AIU group than 
in the NC group (35.1±11.5 vs. 32.5±12.6 years, respectively; 
P=0.041). The AIU patients exhibited a significantly higher rate 
of atopy than the NC group (69.6 vs. 13.2%, respectively; P<0.001) 
and higher serum total IgE (log transformed; 5.1±1.2 vs. 3.6±
1.3 IU/mL respectively; P<0.001).
The genotype frequencies for the two polymorphisms in each 
of CYP2C9 and UGT1A6 and the five polymorphisms in NAT2 
were analyzed and compared between AIU patients and NC 
subjects. The two polymorphisms in CYP2C9 were in linkage 
disequilibrium (/D′/=1, r
2=0.067). The frequency of the minor 
C allele of CYP2C9 −1188T>C was significantly higher in the 
AIU group than in the NC group (P=0.005), and remained sig-
nificant after a multiple comparison (Pcorr=0.03). The frequen-
cy of the variant genotype CC of CYP2C9 −1188T>C was also 
higher in the AIU patients compared with the controls in both 
the co-dominant (P=0.007) and recessive models (P=0.012). 
Table 1.  Genotype and allele frequencies of CYP2C9, UGT1A6 and NAT2 gene 
polymorphisms
    AIU (n=148) NC (n=260) P value Pcorr
CYP2C9 -1188 T>C TT 35 (23.6%) 96 (36.9%) 0.007 0.042
(Promoter) TC 81 (54.7%) 126 (48.5%) 0.070 NS
(rs 4918758) CC 32 (21.6%) 38 (14.6%) 0.012 NS
q. 0.49 0.388 0.005 0.030
CYP2C9*3 A1075C AA 136 (91.9%) 233 (89.6%) 0.385 NS
(Coding exon) AC 12 (8.1%) 26 (10.0%) 1 NS
(rs 1057910) CC 0 (0%) 1 (0.4%) 0.441 NS
q. 0.41 0.54 0.397 NS
    AIU (n=146) NC (n=258) P value Pcorr
UGT1A6 T181A A>G AA 85 (58.2%) 152 (58.9%) 0.762 NS
(Exon) AG 54 (37%) 94 (36.4%) 0.988 NS
(rs 2070959) GG 7 (4.8%) 12 (4.7%) 0.723 NS
q. 0.233 0.229 0.892 NS
UGT1A6 R184S A>C AA 79 (54.5%) 151 (58.5%) 0.251 NS
(Exon) AC 55 (37.9%) 94 (36.4%) 0.355 NS
(rs 1105879) CC 11 (7.6%) 13 (5.0%) 0.333 NS
q. 0.266 0.233 0.296 NS
    AIU (n=148) NC (n=260) P value Pcorr
NAT2 -9796 T>A TT 86 (58.1%) 157 (60.4%) 0.979 NS
(Promoter) AT 58 (39.2%) 95 (36.5%) 0.821 NS
(rs 4646244) AA 4 (2.7%) 8 (3.1%) 0.847 NS
q. 0.223 0.213 0.249 NS
NAT2197 G>A AA 85 (57.4%) 162 (62.3%) 0.509 NS
(Exon) AG 59 (39.9%) 90 (34.6%) 0.979 NS
(rs1799930) GG 4 (2.7%) 8 (3.1%) 0.452 NS
q. 0.226 0.204 0.450 NS
NAT2 286 A>G AA 118 (79.7%) 196 (75.4%) 0.336 NS
(Exon) AG 28 (18.9%) 59 (22.7%) 0.669 NS
(rs1799931) GG 2 (1.4%) 5 (1.9%) 0.346 NS
q. 0.108 0.133 0.305 NS
    AIU (n=148) NC (n=259) P value Pcorr
NAT2 -9601 A>G AA 42 (28.4%) 65 (25.1%) 0.47 NS
(Promoter) AG 79 (53.4%) 139 (53.7%) 0.527 NS
(rs 4646267) GG 27 (18.2%) 55 (21.2%) 0.402 NS
q. 0.449 0.481 0.388 NS
NAT2 -9306 A>G AA 102 (68.9%) 156 (60.2%) 0.176 NS
(Promoter) AG 42 (28.4%) 96 (37.1%) 0.783 NS
(rs 4345600) GG 4 (2.7%) 7 (2.7%) 0.11 NS
  q. 0.169 0.212 0.134 NS
P values were applied by binary logistic regression with sex and age. P<0.05 
was considered to be significant. P value was further tested using multiple 
comparisons, as indicated, Pcorr for AIU vs. NC.
AIU, aspirin intolerant urticaria; NC, normal control; CYP2C9, cytochrome P450C9; 
UGT1A6, UDP-glucuronosyltransferase 1A6; NAT2, N-acetyl transferase 2.Polymorphisms of Metabolizing Enzymes in  Urticaria
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In addition, the relationship between the CYP2C9 −1188T>C 
polymorphism and AIU remained significant after a multiple 
comparison test (Pcorr=0.042 [co-dominant model] for AIU vs. 
NC; Table 1). Using Power Analysis and Sample Size (PASS, 
2008), the power of this genetic association study was calculat-
ed to be 74% for detecting an effect size (W) of 0.1430 using 2 
degrees of freedom with the χ2 test, at a significance level (alpha) 
of 0.05. The frequency of haplotype 2 [CA] was significantly 
higher in the AIU group compared with the NC group in both 
Table 2.  Haplotype frequencies of CYP2C9, UGT1A6 and NAT2 gene polymor-
phisms
CYP   AIU (n=148) NC (n=259) P value Pcorr
ht1 (TA) +/+ 35 (23.6%) 96 (37.1%) 0.006 0.036
+/- 81 (54.7%) 126 (48.6%) 0.056 0.336
-/- 32 (21.6%) 37 (14.3%) 0.012 0.072
ht2 (CA) +/+ 26 (17.6%) 29 (11.2%) 0.006 0.036
+/- 87 (58.8%) 134 (51.7%) 0.012 0.072
-/- 35 (23.6%) 96 (37.1%) 0.079 0.474
ht3 (CC) +/+ NA NA 0.522 1
+/- 6 (4.1%) 8 (3.1%) 0.522 1
-/- 142 (95.9%) 251 (96.9%) NA NA
UGT   AIU (n=145) NC (n=258) P value Pcorr
ht1 (AA) +/+ 79 (54.5%) 151 (58.5%) 0.251 1
+/- 55 (37.9%) 94 (36.4%) 0.355 1
-/- 11 (7.6%) 13 (5.0%) 0.333 1
ht2 (GC) +/+ 7 (4.8%) 12 (4.7%) 0.887 1
+/- 54 (37.2%) 94 (36.4%) 0.688 1
-/- 84 (57.9%) 152 (58.9%) 0.977 1
ht3 (AC) +/+ NA NA 0.01 1
+/- 9 (6.2%) 2 (0.8%) 0.01 1
-/- 136 (93.8%) 256 (99.2%) NA 1
NAT2   AIU (n=148) NC (n=258) P value Pcorr
ht1 (TAAGG) +/+ 39 (26.4%) 65 (25.2%) 0.572 1
+/- 82 (55.4%) 138 (53.5%) 0.459 1
-/- 27 (18.2%) 55 (21.3%) 0.848 1
ht2 (AAAAG) +/+ 4 (2.7%) 8 (3.1%) 0.663 1
+/- 57 (38.5%) 89 (34.5%) 0.614 1
-/- 87 (58.8%) 161 (62.4%) 0.969 1
ht3 (TAGGA) +/+ 2 (1.4%) 4 (1.6%) 0.256 1
+/- 25 (16.9%) 58 (22.5%) 0.225 1
-/- 121 (81.8%) 196 (76.0%) 0.873 1
ht4 (TAGGG) +/+ 1 (0.7%) 1 (0.4%) 0.202 1
+/- 17 (11.5%) 46 (17.8%) 0.154 1
-/- 130 (87.8%) 211 (81.8%) 0.651 1
ht5 (TAAGG) +/+ 0 (0%) 2 (0.8%) 0.42 1
+/- 20 (13.5%) 23 (8.9%) 0.273 1
  -/- 128 (86.5%) 233 (90.3%) 0.999 1
P values were applied by binary logistic regression with sex and age.
the co-dominant (P=0.006; Pcorr=0.036) and dominant models 
(P=0.012) (Table 2).
There was no significant difference in allele, genotype, or hap-
lotype frequencies of the UGT1A6 and NAT2 genetic polymor-
phisms between the AIU and NC groups. Clinical parameters, 
including atopic status, serum total IgE levels, and autoanti-
body levels, did not differ between any of the genotypes for any 
of the polymorphisms.
We analyzed the genotype frequencies for two SNPs in both 
CYP2C9 and UGT1A6, and five SNPs in NAT2, and compared 
them between AIU patients and normal control subjects in a 
Korean population. This is the first study to investigate the SNPs 
of CYP2C9, UGT1A6, and NAT2 in AIU patients. Among the 
nine polymorphisms in the three metabolic enzyme genes ana-
lyzed, CYP2C9 −1188T>C showed a significant association 
with the AIU phenotype. The frequencies of the minor C allele 
and the CC genotype of CYP2C9 −1188T>C were significantly 
higher in the AIU group compared with the NC group. There 
was no significant difference in allele, genotype, or haplotype 
frequencies of the UGT1A6 and NAT2 polymorphisms between 
the AIU and NC groups.
CYP2C9 is involved in the metabolism of many therapeutic 
agents, including non-steroidal anti-inflammatory drugs, oral 
anticoagulants, and angiotensin receptor antagonists. The me-
tabolism of non-steroidal anti-inflammatory drugs involves ox-
idation by CYP enzymes and conjugation, particularly gluc-
uronidation, by phase II enzymes. Aspirin is deacetylated to 
salicylic acid and is further metabolized by glucuronidation, 
hydroxylation, and glycine conjugation, with CYP2C9 playing a 
major role in the metabolic process.
5 Genetic polymorphisms 
in CYP2C9 have been associated with cutaneous adverse reac-
tions induced by diphenylhydantoin.
9 The effects of inter-indi-
vidual differences in UGT1A6 and CYP2C9 genotypes on ASA 
metabolism have been described in colon adenoma.
5 Recently, 
CYP2C19 and CYP2C9 genetic polymorphisms were shown to 
be significantly associated with an increased risk for the devel-
opment of antituberculosis drug-induced maculopapular erup-
tion in the Korean population.
10 Collectively, these findings sug-
gest that the C allele may be involved in the pathogenesis of AIU; 
however, further studies of CYP2 enzyme activity are needed.
The NAT2 gene variants and its subphenotypes have been 
linked to the development of asthma. Additionally, the NAT2 
slow acetylator phenotype may be a determinant in a patient’s 
susceptibility to asthma.
11 Another study indicated that SNPs in 
the NAT2 gene are closely associated with asthma-related traits 
such as high serum IgE and blood eosinophil counts, and aspi-
rin hypersensitivity in asthmatic subjects.
7,8 Significant associa-
tions between UGT1A6 T181A gene polymorphisms and asth-
ma susceptibility have also been reported.
12 However, the re-
sults of this study did not show a relationship between NAT2 or 
UGTA6 polymorphisms and AIU in a Korean population.
In summary, we identified a statistically significant associa-Palikhe et al.
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tion between the C allele of CYP2C9 −1188T>C and AIU, sug-
gesting that this allele may modulate the risk for, and contribute 
to, the development of the AIU phenotype.
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